*Thumbnail*- ‘Antibody Cocktail’
New Weapon against COVID-19
Mohabbat Singh an 84-year-old man from Haryana became the first person in India to administer COVID-19 antibody cocktail. He successfully got the drug over 30 min intravenous supply and has been discharged. In this video we will discuss what COVID-19 antibody cocktail is, its features, usage and price. So, let’s get started
*What is COVID-19 Antibody Cocktail?*
It is a combination of casirivimab and imdevimab and has been developed by pharmaceutical giant Roche. Casirivimab and Imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2. They block the virus’ attachment and entry into human cells.
It works against COVID-19 and can be procured subject to medical prescription by registered medical practitioners.
Recently, Central Drugs Standards Control Organisation (CDSCO) approved the Emergency Use Authorisation of the antibody cocktail in India. Along with India, US and many EU countries have allowed the emergency use authorisation.
The cocktail drug is being developed by Roche will be distributed across the country through Cipla.
V. Simpson Emmanuel, MD and CEO of Roche Pharma India says that “Roche is deeply committed to support the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens.”
Roche cocktail managed to gain public attention after it was administered to former US President Donald Trump. It was administered when he was COVID positive. The antibody cocktail is effective against the B.1.617 variant, which was found in India.
The cocktail reduces the risk of losing its neutralisation potency against new emerging variants. It has been shown to reduce hospitalisations in COVID-19 patients who are at a high risk of developing severe disease.
Administration process of the cocktail takes around 20-30 minutes. 2.5 ml , 2 each of Casirivimab & Imdevimab get administered concurrently at four different sites on the abdomen or thigh. During the administration, the patient is continuously monitored. Patients are also kept under observation after post the infusion process
All the vials need to be stored at 2°C to 8°C. 1 vial can be used for two patients. So if the doctor opens a vial for patient 1 , then patient 2 should also be administered within 48 hours if vials are stored at 2°C to 8°C.
The first batch is available in India and the second batch is expected to be available by mid of June. Around 1 lakh packs will be available which can effectively be given to 2 lakh patients. Cipla is taking charge of pan-India distribution and leading hospitals and COVID treatment centers will administer this drug
The price for each patient dose will be Rs 59,750 inclusive of all taxes. MRP for the multi dose pack (each pack can treat two patients) is Rs 1,19,500
Along with rapid vaccination, this antibody cocktail is definitely emerging as a new weapon in India’s fight against covid-19. That’s all for today, thanks for watching . Take care and make sure to get yourself vaccinated.